Ultragenyx Pharmaceutical Inc. (RARE)
NASDAQ: RARE · Real-Time Price · USD
14.86
-0.44 (-2.88%)
Oct 13, 2026, 3:51 PM EDT - Market open
Ultragenyx Pharmaceutical Employees
Ultragenyx Pharmaceutical had 1,371 employees as of December 31, 2025. The number of employees increased by 77 or 5.95% compared to the previous year. That makes Ultragenyx Pharmaceutical the 12,662nd largest employer in the world and 1,986th in the United States.
Employees
1,371
Change (1Y)
77
Growth (1Y)
5.95%
Revenue / Employee
$522,976
Profits / Employee
-$427,425
Market Cap
1.46B
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 1,371 | 77 | 5.95% |
| Dec 31, 2024 | 1,294 | 18 | 1.41% |
| Dec 31, 2023 | 1,276 | -35 | -2.67% |
| Dec 31, 2022 | 1,311 | 192 | 17.16% |
| Dec 31, 2021 | 1,119 | 226 | 25.31% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Ascentage Pharma Group International | 828 |
| Immunocore Holdings | 524 |
| uniQure | 221 |
| Omeros | 175 |
| Stoke Therapeutics | 170 |
| Innoviva | 159 |
| Maze Therapeutics | 141 |
| Rapport Therapeutics | 84 |
RARE News
- 6 days ago - Ultragenyx to sell Rare Pediatric Disease Priority Review Voucher for $210M - TheFly
- 6 days ago - Ultragenyx Enters into Agreement to Sell Rare Pediatric Disease Priority Review Voucher for $210 Million - GlobeNewsWire
- 11 days ago - Ultragenyx Announces Marketing Authorisation Application (MAA) Submission to the European Medicines Agency (EMA) for the First Investigational Gene Therapy for MPS IIIA (Sanfilippo Syndrome Type A) - GlobeNewsWire
- 22 days ago - Ultragenyx price target raised to $18 from $16 at Evercore ISI - TheFly
- 22 days ago - Ultragenyx price target raised to $35 from $32 at Barclays - TheFly
- 25 days ago - Ultragenyx price target raised to $20 from $18 at Morgan Stanley - TheFly
- 25 days ago - Abeona Therapeutics ‘congratulated’ Ultragenyx on U.S FDA approval of UX111 - TheFly
- 25 days ago - Ultragenyx price target raised to $39 from $37 at Canaccord - TheFly